which semaglutide is fda approved for Weight Loss: How It Works, Comparisons, and More Semaglutide Receives FDA Approval for

A 48-week Phase 2 trial reported in The Lancet in 2025 showed mean weight reduction ranging from approximately 9% at the lowest dose to 20% at the highest dose, compared with 0.4% on placebo

Shi S, Shuang S, Xiangdong L, Guoqiang Z, Feng D, Wenshuang Z, et al

Health conditions that can cause low potassium Several health conditions may be linked to low potassium, such as: Eating disorders Cushing's syndrome and other adrenal disorders Gitelman syndrome Liddle syndrome Bartter syndrome Fanconi syndrome Kidney disease Women tend to get hypokalemia more often than men

Semaglutide begins to reduce appetite within the first week, with the most significant effects typically occurring after 2-4 weeks of treatment